Trials
8 active
19 in total · 7 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Participants will receive quizartinib at 60 mg/day orally once daily”In the company’s words, NCT06578247 on ClinicalTrials.gov
- Tested for
- Leukemia (2 trials), Acute Myeloid Leukemia (2 trials), Hepatic Impairment
- Main trialPhase 3
- “This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).”In the company’s words, NCT06578247 on ClinicalTrials.gov
- Other names
- Test Product · VANFLYTA · AC220
Other drugs for Leukemia
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- LisaftoclaxAscentage Pharma Group Inc. · Phase 3
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
Coming up3
- 1 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 6 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 26 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Jun 2030 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | |
| Phase 2Recruiting | 6 Jun 2028 | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | |
| Phase 1/2Active, not recruiting | 1 May 2027 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | |
| Phase 1Recruiting | 31 Oct 2026 | Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment | |
| Phase 3Completed | 22 Feb 2018 | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | |
| Phase 3Completed | 13 Aug 2021 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) | |
| Phase 1Completed | 19 Oct 2017 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | |
| Phase 1Completed | 14 Oct 2020 | A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants | |
| Phase 1Terminated | 1 Apr 2021 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | |
| Phase 1Completed | 11 Jun 2021 | A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects | |
| Phase 1Completed | 22 Jul 2021 | A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment | |
| Phase 1Completed | 3 Mar 2022 | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | |
| Phase 1Completed | 9 Dec 2024 | Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects | |
| Phase 1Completed | 12 Jun 2025 | A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate | |
| Phase 2Authorised | not given | A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML patients (A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium) | |
| Phase 4Authorised | not given | MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL (RESOLVE trial). | |
| Phase 1/2Ended | not given | A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy | |
| Phase 3Authorised | not given | A randomized phase III, global, multicentre, open label clinical trial comparing Venetoclax Azacitidine and Quizartinib vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy. | |
| Phase 3/4Authorised | not given | Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026